Melbourne – October 4, 2026 -- CSL and Alentis Therapeutics have signed an exclusive global collaboration to develop and commercialize lixudebart, a potential first-in-class therapy targeting claudin-1 for rare kidney and liver diseases, with CSL paying Alentis US$355 million upfront and up to US$1.2 billion in commercial milestones.

Sydney – October 01, 2026 -- Silicon Quantum Computing (SQC) and Schneider Electric have advanced to Stage 2 of Australia's Critical Technologies Challenge Program (CTCP), securing A$3.6 million (US$2.5 million) in government funding after their quantum-enhanced forecasting trial delivered an average 20% accuracy improvement, with peak gains of 41%.

London – October 01, 2026 -- Curaleaf International's Que Medical Inhalation Device (QMID) has become the first cannabis inhalation device to secure registration from Australia's Therapeutic Goods Administration, clearing the way for clinicians to prescribe a standardized-dosing device in a market that has treated more than one million patients since 2016.

New York – October 01, 2026 -- Sharon AI Holdings Inc. (NASDAQ: SHAZ) has closed its inaugural US$356 million committed senior secured, GPU-backed SPV debt facility, priced at a fixed rate of 9.95% excluding fees.

Beijing and Tel Aviv – October 01, 2026 -- ADAMA Ltd. (SZSE: 000553) has launched Actavan®, a plant-based fungicide for grapes, in Australia and New Zealand, offering growers a zero-residue tool against Botrytis with no pre-harvest interval.

Brisbane – September 30, 2026 -- Datamine has launched Expenditure Watch 2.0, a redesigned web-based platform that gives mining and exploration companies centralized visibility into expenditure compliance across tenement portfolios.

Brisbane – September 30, 2026 -- The EATP Pegasus long endurance drone completed a nearly two-hour test flight covering more than 75 kilometres on a single Li-S Energy lithium sulfur battery pack, landing safely with battery capacity to spare.

Groton, Conn. – September 30, 2026 -- Astrocyte Pharmaceuticals Inc. has closed a $9.5 million Series B financing round to advance Phase 2 development of AST-004, its cerebroprotective therapy for concussion, traumatic brain injury (TBI) and stroke. The round brings total capital raised by the clinical-stage biotech, including grants, to $40 million.

Sydney – September 29, 2026 -- First Graphene Limited (ASX: FGR) has signed a 36-month Strategic Partner Agreement with UK-based Vector Companies Group Limited, coinciding with Vector's commercial launch of Peltyr, a printed heat flux sensor incorporating First Graphene's PureGRAPH graphene material.

Calgary – September 29, 2026 -- Providence Therapeutics Holdings, Inc. has formed its first Clinical Advisory Board to guide development of its therapeutic mRNA cancer vaccine programs, including a personalized vaccine for pediatric brain cancer and off-the-shelf precision therapies for solid tumors.

Chief Medical Officer Leon Rozen chairs new four-member advisory panel

Dr. Rozen leads the board, which brings in Ezra Cohen, MD; Melinda Merchant, MD, PhD; and John Powderly, MD, to steer clinical strategy for the company's cancer vaccine pipeline.